{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:11:36Z","timestamp":1781842296545,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Basic Research Program of Ningxia Province of China","award":["2025AAC030764"],"award-info":[{"award-number":["2025AAC030764"]}]},{"name":"Health Re-search Program on Ningxia","award":["2025-NWQP-B002"],"award-info":[{"award-number":["2025-NWQP-B002"]}]},{"name":"Xidian University Specially Funded Project for Interdisciplinary Exploration","award":["TZJH2024029, TZJH2024030"],"award-info":[{"award-number":["TZJH2024029, TZJH2024030"]}]},{"name":"Natural Science Basic Research Key Program of Shaanxi Province","award":["2024JC-ZDXM-47"],"award-info":[{"award-number":["2024JC-ZDXM-47"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260473"],"award-info":[{"award-number":["82260473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Basic Research Key Program of Ningxia Province of China","award":["2024AAC02079"],"award-info":[{"award-number":["2024AAC02079"]}]},{"name":"State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund","award":["SKL-HIDCA-2024-NX1"],"award-info":[{"award-number":["SKL-HIDCA-2024-NX1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04436-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:16:21Z","timestamp":1776057381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A \u201cone-two punch\u201d strategy to reverse immunosuppressive metabolism and activate T-cell immunity for enhanced cancer checkpoint immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Peng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuoye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"4436_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"D Wang","year":"2022","unstructured":"Wang D, Wu X, Sun Y. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target therapy. 2022;7:331.","journal-title":"Signal Transduct Target therapy"},{"key":"4436_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, Boussiotis VA. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat cancer. 2025;6:924\u201337.","journal-title":"Nat cancer"},{"key":"4436_CR3","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309\u201337.","journal-title":"Cell"},{"key":"4436_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discovery. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discovery"},{"key":"4436_CR5","doi-asserted-by":"crossref","unstructured":"Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N. and M. Provencio Pulla, Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer, Journal of clinical oncology 43 (2025): 1453\u20131462.","DOI":"10.1200\/JCO-24-02239"},{"key":"4436_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cam4.371","volume":"4","author":"LH Camacho","year":"2015","unstructured":"Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4:661\u201372.","journal-title":"Cancer Med"},{"key":"4436_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41586-025-09679-4","volume":"648","author":"PB Tan","year":"2025","unstructured":"Tan PB, Verschoor YL, van den Berg JG, Balduzzi S, Kok NFM, Ijsselsteijn ME, Moore K, Jurdi A, Tin A, Kaptein P, van Leerdam ME, Haanen JBAG, Voest EE, de Miranda NFCC, Schumacher TN, Wessels LFA, Chalabi M. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. Nature. 2025;648:726\u201335.","journal-title":"Nature"},{"key":"4436_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"4436_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825\u201363.","journal-title":"Cancer Cell"},{"key":"4436_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"4436_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target therapy. 2025;10:227.","journal-title":"Signal Transduct Target therapy"},{"key":"4436_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","volume":"25","author":"CJ Imianowski","year":"2025","unstructured":"Imianowski CJ, Chen Q, Workman CJ, Vignali DAA. Regulatory T cells in the tumour microenvironment. Nat Rev Cancer. 2025;25:703\u201322.","journal-title":"Nat Rev Cancer"},{"key":"4436_CR13","doi-asserted-by":"crossref","unstructured":"Herhaus L, Gestal-Mato U, Eapen VV, Ma\u010dinkovi\u0107 I, Bailey HJ, Prieto-Garcia C, Misra M, Jacomin AC, Ammanath AV, Bagari\u0107 I, Michaelis J, ollrath J, haskara RM, \u00fcndgen G, ovarrubias-Pinto A, usnjak K, J. \u00f6ller, ikandi A, ibi\u010di\u0107 S, Bopp T, Noort GJ, Langer JD, Weigert A, Harper JW, Mancias JD, Dikic I. IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion, Cell 187 (2024): 7285\u20137302.","DOI":"10.1016\/j.cell.2024.09.048"},{"key":"4436_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25:353\u201369.","journal-title":"Nat Rev Immunol"},{"key":"4436_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S, Liang J, Tang Y, Su M, Luo X, Yang Y, Shi Y, Wang H, Zhou Y, Liao Q. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.","journal-title":"Mol Cancer"},{"key":"4436_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target therapy. 2023;8:70.","journal-title":"Signal Transduct Target therapy"},{"key":"4436_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","volume":"56","author":"J Park","year":"2023","unstructured":"Park J, Hsueh PC, Li Z, Ho PC. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. Immunity. 2023;56:32\u201342.","journal-title":"Immunity"},{"key":"4436_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s42114-025-01335-9","volume":"8","author":"X Gu","year":"2025","unstructured":"Gu X, Yu T, Nie W, Shi H, Jin K, Zhang W, Cai J. Intelligent nanoparticles loaded simultaneously with anti-PD-L1 and anti-CTLA-4 for photothermal immunotherapy of lung cancer. Adv Compos hybrid Mater. 2025;8:274.","journal-title":"Adv Compos hybrid Mater"},{"key":"4436_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41419-024-06776-6","volume":"15","author":"W Yang","year":"2024","unstructured":"Yang W, Sun Q, Zhang X, Zheng L, Yang X, He N, Pang Y, Wang X, Lai Z, Zheng W, Zheng S, Wang W. A novel doxorubicin\/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy. Cell Death Dis. 2024;15:386.","journal-title":"Cell Death Dis"},{"key":"4436_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.006","volume":"177","author":"K O\u2019Byrne","year":"2023","unstructured":"O\u2019Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. Lung Cancer. 2023;177:11\u201320.","journal-title":"Lung Cancer"},{"key":"4436_CR21","doi-asserted-by":"publisher","first-page":"117961","DOI":"10.1016\/j.ejmech.2025.117961","volume":"297","author":"F Coburn","year":"2025","unstructured":"Coburn F, Nsereko Y, Armstrong A, Musaimi OA. Peptide inhibitors: Breaking cancer code. Eur J Med Chem. 2025;297:117961.","journal-title":"Eur J Med Chem"},{"key":"4436_CR22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41565-025-02022-y","volume":"20","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhao M, Li J, Xu R, Liang J, Jiang Q, Peng X, Tong A, Min L, Lin Y, Zhang X, Fan Y, Sun Y. Black phosphorus nanosheets boost mitochondrial oxidative phosphorylation improving immunotherapy outcomes. Nat Nanotechnol. 2025;20:1843\u201355.","journal-title":"Nat Nanotechnol"},{"key":"4436_CR23","first-page":"167","volume":"25","author":"A Suvac","year":"2025","unstructured":"Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25:167\u201388.","journal-title":"Nat Rev Cancer"},{"key":"4436_CR24","doi-asserted-by":"crossref","unstructured":"Soragni A, Knudsen ES, O\u2019Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025;25:613\u201333.","DOI":"10.1038\/s41568-025-00824-9"},{"key":"4436_CR25","doi-asserted-by":"publisher","first-page":"122678","DOI":"10.1016\/j.biomaterials.2024.122678","volume":"311","author":"Y Xia","year":"2024","unstructured":"Xia Y, Zou C, Kang W, Xu T, Shao R, Zeng P, Sun B, Chen J, Qi Y, Wang Z, Lin T, Zhu H, Shen Y, Wang X, Guo S, Cui D. Invasive metastatic tumor-camouflaged ROS responsive nanosystem for targeting therapeutic brain injury after cardiac arrest. Biomaterials. 2024;311:122678.","journal-title":"Biomaterials"},{"key":"4436_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jconrel.2023.05.015","volume":"358","author":"A Dey","year":"2023","unstructured":"Dey A, Jeon J, Yoon B, Li Y, Park JH. Cascade-amplified self-immolative polymeric prodrug for cancer therapy by disrupting redox homeostasis. J Controlled Release. 2023;358:555\u201365.","journal-title":"J Controlled Release"},{"key":"4436_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/cells10020439","volume":"10","author":"V Innao","year":"2021","unstructured":"Innao V, Rizzo V, Allegra AG, Musolino C, Allegra A. Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma. Cells. 2021;10:439.","journal-title":"Cells"},{"key":"4436_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.cdd.4402233","volume":"15","author":"Y Chen","year":"2008","unstructured":"Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15:171\u201382.","journal-title":"Cell Death Differ"},{"key":"4436_CR29","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1021\/acsnano.3c11464","volume":"18","author":"H Xiao","year":"2024","unstructured":"Xiao H, Li X, Liang S, Yang S, Han S, Huang J, Shuai X, Ren J. Dual-responsive nanomedicine activates programmed antitumor immunity through targeting lymphatic system. ACS Nano. 2024;18:11070\u201383.","journal-title":"ACS Nano"},{"key":"4436_CR30","doi-asserted-by":"publisher","first-page":"e2501953","DOI":"10.1002\/adma.202501953","volume":"37","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yan Y, Liu J, Xia H, Zhou J, Cui Y, Huang X, Chang J, Zhang W, Chen W, Zhang Q, Wang S, Wang Y, Chen B. An endoplasmic reticulum stress-specific nanoinducer selectively evokes type-II immunogenic cell death for pyroptotic cancer immunotherapy. Adv Mater. 2025;37:e2501953.","journal-title":"Adv Mater"},{"key":"4436_CR31","doi-asserted-by":"publisher","first-page":"270009","DOI":"10.1002\/EXP.70009","volume":"5","author":"F Xia","year":"2025","unstructured":"Xia F, Lu Y, Gong Z, Tu Q, Liang S, Wang C, Yao H, Zhong L, Fu Y, Guo P, Hou Y, Zhou X, Zou L, Gan L, Chen W, Yan J, Zhang J, Pang H, Meng Y, Shi Q, Pan C, Tao X, Wang J, Du Q, Qiu C. Cancer immunotherapy based on the bidirectional reprogramming of the tumor microenvironment by a brakes off\/step on the accelerator core-shell manganese phosphate\/siPD\u2010L1 modulator. Exploration. 2025;5:270009.","journal-title":"Exploration"},{"key":"4436_CR32","doi-asserted-by":"crossref","unstructured":"Hu T, Wang T, Chan L, Lu Y, Xie H, Li M, Yang Y, Su L, Zhang X, Song J, Wang Y, Tan C, Liang R. Suppressing reverse intersystem crossing by confining organic molecules within LDH interlayers for near-infrared-II photodynamic immunotherapy. Adv Mater. 2025;38:e14105.","DOI":"10.1002\/adma.202514105"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04436-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:15:50Z","timestamp":1779675350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04436-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4436"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04436-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}